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endogenous opioids that act on their respective receptors. In this study, we investigated
the involvement of endogenous opioids in a2-adrenoceptor agonist xylazine-induced
central antinociception. The nociceptive threshold for thermal stimulation was measured
in Swiss mice using the tail-flick test. The drugs were administered via the intracerebro-
ventricular route. Probabilities less than 5% (po0.05) were considered to be statistically
significant (ANOVA/Bonferroni’s test). Our results demonstrated that opioid receptor
antagonist naloxone and m-opioid receptor antagonist clocinnamox, but not d-opioid
receptor antagonist naltrindole and k-opioid receptor antagonist nor-binaltorphimine,
antagonized xylazine-induced central antinociception. These data provide evidence for
the involvement of endogenous opioids and m-opioid receptors in xylazine-induced central
antinociception. In contrast, d- and k-opioid receptors do not appear to be involved in this
effect. The results contribute to a greater understanding of the central antinociceptive
mechanisms of a drug widely used in veterinary therapy.
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Xylazine is an a2-adrenoceptor agonist (Hsu, 1981) that is
extensively used in veterinary medical practice and animal
experimentation for sedation, antinociception, and muscle
relaxation (Willian et al., 2001). Xylazine exhibits direct, local
anesthetic sensory and motor nerve inhibition in addition to its
spinal cord a2-adrenoceptor-mediated analgesic effects (Knight,
1980). Furthermore, xylazine in combination with other sub-
stances has been useful in many surgical procedures. For
example, xylazine-ketamine mixtures have been used forshort-duration surgery in both wild and domesticated pigs
(Ajadi et al., 2008). Synergistic antinociceptive interactions
between epidurally administered xylazine and lidocaine
induced good-quality antinociception in water buffalo calves
(Singh et al., 2005). Recently, it was observed that xylazine-
tramadol in combination is useful for equine sedation and
analgesia (Seo et al., 2011).
Xylazine’s antinociceptive actions were initially investi-
gated using the murine acetic acid-induced writhing test by
Bentley et al. (1977). Others observed that the antinociceptive
effects of intraperitoneal xylazine administration were
Fig. 1 – Antinociception induced by intracerebroventricular
administration of xylazine in mice. Xylazine (Xyl; 5, 10 and
20 lg) was administered 1 min prior to measured in the tail-
flick test. Each line represents the mean7SEM for four mice
per group.  indicates a significant difference compared to
Sal-injected group (ANOVAþBonferroni test; interaction:
Df¼12, F¼20.96; column factor: Df¼3, F¼82.60; row factor:
Df¼4, F¼101.20; po0.05). Sal, saline (0.5% of Evans blue).
b r a i n r e s e a r c h 1 5 0 6 ( 2 0 1 3 ) 5 8 – 6 3 59antagonized by yohimbine, but not by the opioid receptor
antagonist naloxone. These data suggest that this effect is
dependent on an a2-adrenoceptor-mediated, and not on an
opioid-mediated, mechanism (Browing et al., 1982; Zemlan
et al., 1980). It was additionally shown that the spinal and
systemic antinociceptive effects of xylazine are independent
of the opioid system (Browing et al., 1982; Goodchild et al.,
1996).
Conversely, evidence exists that a2-adrenoceptor agonists
activate opioid receptors via endogenous opioid release.
In 1988, it was shown that a2-adrenoceptor agonist clonidine-
induced peripheral antinociception was prevented by the opioid
antagonist naloxone (Nakamura and Ferreira, 1988). Similarly,
our group observed that naloxone antagonized xylazine-induced
peripheral antinociception in rats (Romero et al., 2009).
Endogenous opioids have been implicated in antinocicep-
tion induced by several compounds including non-steroidal
anti-inflammatory drugs (Rezende et al., 2009), cannabinoids
(Cox and Welch, 2004) and natural coffee-derived diterpenes
(Guzzo et al., 2012). They act mainly through three types of
opioid receptors m, d and k (Singh et al., 1997). Centrally, the
periaqueductal gray area (PAG) contains high concentrations
of endogenous opioid peptides b-endorphin and Met-enke-
phalin, and opioid receptors m and d. Activation of any of
these opioid receptors by b-endorphin, morphine or other
opioids administered into the PAG produces potent antinoci-
ception at supraspinal sites (Terashvili et al., 2008).
To elucidate the mechanisms involved in supraspinal
xylazine administration, the aim of the present study was
to determine whether endogenous opioids are involved in
xylazine-induced central antinociception and to identify the
opioid receptors that are involved.2. Results
2.1. Antinociceptive effect of xylazine
The intracerebroventricular administration of xylazine (5, 10
and 20 mg) produced an antinociceptive response, in a dose-
dependent manner (Fig. 1). There was no statistical difference
between the 10 and 20 mg doses, being the dose of 10 mg
chosen for the present study.2.2. Antagonism of xylazine-induced antinociception by
naloxone or clocinnamox
As shown in Fig. 2a and b, the intracerebroventricular admin-
istration of naloxone (2.5 and 5 mg) or clocinnamox (2 and 4 mg)
inhibited the xylazine-induced central antinociception (10 mg),
respectively. The highest effective dose of the antagonists
per se did not modify the withdrawal threshold (Fig. 2a and b).2.3. Effect of naltrindole and nor-binaltorphimine on
xylazine-induced antinociception
The intracerebroventricular administration of naltrindole
(6 and 12 mg; Fig. 3a) and nor-binaltorphimine (10 and 20 mg;
Fig. 3b) did not modify the central antinociception of xylazine(10 mg). These drugs did not significantly modify the nocicep-
tive threshold in control mice.3. Discussion
Opioid peptides have been implicated in antinociception
induced by several compounds, including non-steroidal anti-
inflammatory drugs (Rezende et al., 2009), cannabinoids (Cox
and Welch, 2004), natural coffee-derived diterpenes (Guzzo
et al., 2012) and a2-adrenoceptor agonists (Nakamura and
Ferreira, 1988). Our group suggested previously that xylazine
induces peripheral antinociception by releasing endogenous
opioids that act on their receptors (Romero et al., 2009).
Because there is a lack of information regarding opioid peptide
participation in the central analgesic mechanism of xylazine,
the present work investigated this hypothesis.
The antinociceptive effect of xylazine administered
systemically (Bentley et al., 1977; Naves and Freire, 1989),
intrathecally (Goodchild et al., 1996) or intracerebroventricu-
larly (Schmitt et al., 1974) has been described by several
authors. Our results demonstrated that xylazine produced
central antinociceptive effects in the tail-flick test in a dose-
dependent manner, and a 10 mg dose was chosen for the
present study. It has been shown that administration of other
adrenergic agonists intracerebroventricularly induces marked
antinociception to thermal stimuli (Buerkle and Yaksh, 1998;
Pertovaara et al., 1991).
The opioid receptor antagonist naloxone prevented xylazine-
induced central antinociception, suggesting participation of
opioid receptors in this effect. Several reports in the literature
suggest interaction of opioid- and a-adrenoceptor agonists at the
receptor level. In 1974, it was observed that naloxone inhibited
phenoxybenzamine and phentolamine binding to brain homo-
genates (Cicero et al., 1974). Other authors demonstrated that
Fig. 2 – Antagonism induced by intracerebroventricular
administration of naloxone (a) and clocinnamox (b) on the
central antinociception produced by xylazine. Naloxone
(Nal; 2.5 and 5 lg) or clocinnamox (Clo; 2 and 4 lg) were
administered 1 min prior to xylazine (Xyl; 10 lg). These
antagonists did not significantly modify the nociceptive
threshold in control mice. Each line represents the
mean7SEM for four mice per group.  and # indicate a
significant difference compared to (SalþSal) and (SalþXyl
10)-injected controls, respectively (ANOVAþBonferroni test;
interaction: Df¼16, F¼10.96; column factor: Df¼4, F¼42.35;
row factor: Df¼4, F¼31.80; po0.05 (a) and interaction:
Df¼16, F¼2.21; column factor: Df¼4, F¼18.92; row factor:
Df¼4, F¼15.93; po0.05 (b)). Sal, saline (0.5% of Evans blue).
Fig. 3 – Effect of intracerebroventricular administration of
naltrindole (a) and nor-binaltorphimine (b) on the central
antinociception produced by xylazine. Naltrindole (NTD; 6
and 12 lg) or nor-binaltorphimine (NorBni; 10 and 20 lg)
were administered 1 min prior to the xylazile (Xyl; 10 lg).
Each line represents the mean7SEM for 4 mice per group.
 indicates a significant difference compared to Sal-injected
group (ANOVAþBonferroni test; interaction: Df¼16, F¼7.52;
column factor: Df¼4, F¼52.82; row factor: Df¼4, F¼56.49;
po0.05 (a) and interaction: Df¼16, F¼6.37; column factor:
Df¼4, F¼31.83; row factor: Df¼4, F¼52.36; po0.05 (b)) Sal,
saline (0.5% of Evans blue).
b r a i n r e s e a r c h 1 5 0 6 ( 2 0 1 3 ) 5 8 – 6 360phenoxybenzamine caused a dose-dependent displacement of
stereospecifically bound naloxone from mouse brain homoge-
nates (Spiehler et al., 1978). Thus, it has been hypothesized that
a2-adrenoceptor and opioid receptors may be linked, either via
secondary messenger systems or physical membrane interation
(Bentley et al., 1983). Aley and Levine (1997) proposed that the
existence of a m9a2 receptor complex mediating peripheral
antinociception explained the naloxone-mediated inhibition of
peripheral xylazine-induced antinociception.
Naloxone has been useful for receptor affinity determina-
tion of type-selective opioids in mammals; however, nalox-
one preferentially interacts with m binding sites (KD¼3.9 nM),
but also has significant affinity for k-opioid receptors (KD¼16
nM) and less affinity for d-opioid receptors (KD¼95 nM) (Satoh
and Minami, 1995). To clarify which receptor subtype would
be involved in the central antinociceptive effect of xylazine,
highly selective antagonists clocinnamox, naltrindole and nor-
binaltorphimine were used. Clocinnamox is an irreversible m-
opioid receptor antagonist with Ki values of 0.7, 1.9 and 5.7 nM
for mouse m, d and k receptors, respectively (Burke et al., 1994).
Naltrindole has 223- and 346-fold greater activity for d- thanfor m- and k-opioid receptors (Portoghese et al., 1990), and nor-
binaltorphimine shows 27- to 29-fold less potency, respec-
tively, for m and d binding sites compared with k receptors
binding sites (Rothman et al., 1988). The results demonstrated
that clocinnamox, but not naltrindole or nor-binaltorphimine,
antagonized xylazine-induced central antinociception, reinfor-
cing the participation of m-opioid receptors in this effect.
The periaqueductal gray area (PAG) contains high concen-
trations of endogenous opioid peptides b-endorphin and
enkephalin and receptors m and d (Yaksh et al., 1988). Activa-
tion of any of these opioid receptors by PAG administration of
b-endorphin, morphine or other opioids produces potent
antinociception at supraspinal sites and also activates the
descending pain control pathways, which are mediated by
the brainstem rostral ventromedial medulla (RVM) (Basbaum
and Fields, 1984; Pavlovic and Bodnar, 1998; Smith et al.,
1988). The RVM contains m-, d-, and k-opioid receptors and it
is a major locus for the descending control of nociception and
opioid analgesia (Bowker and Dilts, 1988; Gutstein et al., 1998;
Kalyuzhny and Wessendorf, 1998). The analgesia produced by
microinjection of morphine into the PAG is dependent upon
the connection to the RVM and the direct stimulation of the
RVM also can produce potent analgesia (Pan and Fields, 1996;
b r a i n r e s e a r c h 1 5 0 6 ( 2 0 1 3 ) 5 8 – 6 3 61Urban and Smith, 1994). Importantly, the tail-flick response is
modulated in the RVM (Gilbert and Franklin, 2001). Addition-
ally, opioid antagonists administered into the PAG signifi-
cantly reduce both morphine and beta-endorphin analgesia
elicited from the amygdala. This shows the relationship
between the amygdala and PAG in analgesic responsiveness.
However, the co-administration of subthreshold doses of
morphine into both the amygdala and PAG results in a
profound synergistic interaction on the jump test, but not
the tail-flick test (Pavlovic and Bodnar, 1998).
Neurons, astrocytes and microglia express adrenergic
receptors a1, a2 and b (Laureys et al., 2010; Mori et al., 2002;
Peng et al., 2010; Porter and McCarthy, 1997), and astrocytes
are a major central nervous system target for a2-adrenergic
agonists (Hertz et al., 2004). Our data did not directly demon-
strate xylazine activation of a2-adrenoceptor in these loca-
tions, but they can be implicated as potential cellular sites.
In conclusion, our results are the first to suggest that the
central antinociceptive effect of xylazine is associated with
the release of endogenous opioids acting on m-opioid recep-
tors. The results of this work contribute to a greater under-
standing of the central antinociceptive mechanisms of a drug
widely used in veterinary therapy; however, more work needs
to be done to elucidate the relationship between xylazine and
endogenous opioids.4. Experimental procedure
4.1. Animals
The experiments were performed on 25–30 g male Swiss mice
(N¼4 per group) from the CEBIO (The Animal Centre) of the
University of Minas Gerais (UFMG). The mice were housed in
a temperature-controlled room (2371 1C) on an automatic
12-h light/dark cycle (06:00–18:00 h of light phase). All testing
was carried out during the light phase (08:00–15:00 h). Food
and water were freely available until the onset of the experi-
ments. The algesimetric protocol was approved by the Ethics
Committee on Animal Experimentation (CETEA) of UFMG.4.2. Algesimetric method
The tail-flick test used in the present study was conducted in
accordance with the procedure described by D’amour and
Smith (1941) with a slight modification. Briefly, following
restraining of the mouse by one of experimenter’s hand, a
heat source was applied 2 cm from the tip of the tail, and the
time(s) required for the animal to withdraw its tail from the
heat source was recorded as the tail-flick latency. The
intensity of the heat was adjusted so that the baseline
latencies were between 3 and 4 s. To avoid tissue damage,
the cut-off time was established at 9 s. The baseline latency
was obtained for each animal before drug administration
(zero time) by calculating an average of three consecutive
trials. To reduce stress, mice were habituated to the appara-
tus 1 day prior to conducting the experiments.4.3. Intracerebroventricular injection (i.c.v.)
Animals were constrained by a special device, which immobi-
lizes their body, except for their head. With one hand the
experimenter restrained the animal head and then injected the
drugs into its right lateral ventricle, by intracerebroventricular
route using a Hamilton syringe of 5 ml. The site of injection was
1mm from either side of the midline on a line drawn through
the anterior base of the ears (modified from Haley and
Mccormick, 1957). The syringe was inserted perpendicularly
through the skull into the brain in the profundity of 2mm and
2 ml of solution was injected. For ascertaining the areas in the
brain ventricular system into which the drugs penetrated,
dilution of the drugs in Evans blue 0.5% was realized and the
brain were sectioned for confirmation after experiments under
anesthesia.4.4. Experimental protocol
All drugs were i.c.v. administered into the lateral ventricle.
Naloxone, clocinnamox, naltrindole and nor-binaltorphimine
were administered 1 min prior to the xylazine.
The nociceptive threshold was always measured in the
mouse tail and the measurements of latency were performed
at the following times: 0, 5, 10, 15 and 30 min. The protocol
above was assessed in pilot experiments to determine the
best moment for the injection of each substance.4.5. Statistical analysis
Data were analyzed statistically by two-way analysis of
variance (ANOVA) with post hoc Bonferroni’s test for multiple
comparisons. Probabilities less than 5% (po0.05) were con-
sidered to be statistically significant.4.6. Chemicals
The following drugs and chemicals were used: a2-adrenocep-
tor agonist xylazine (Sigma, USA), opioid receptor antagonist
naloxone (Sigma), m-opioid receptor antagonist clocinnamox
(Tocris, USA), d-opioid receptor antagonist naltrindole (Tocris)
and k-opioid receptor antagonist nor-binaltorphimine (Sigma).
All drugs were dissolved in saline and injected in a volume of
2 ml into the lateral ventricle. The saline used for dilution of all
drugs contained 0.5% of Evans blue.Conflicts of interest
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